On April 28, 2022 BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, reported three poster presentations relating to lead asset plinabulin at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 3-7, 2022, in Chicago, Illinois and virtually (Press release, BeyondSpring Pharmaceuticals, APR 28, 2022, View Source;utm_medium=rss&utm_campaign=beyondspring-announces-three-poster-presentations-at-the-american-society-of-clinical-oncology-asco-annual-meeting [SID1234613099]). One of the posters includes an analysis of the use of granulocyte colony-stimulating factor (G-CSF) to prevent febrile neutropenia (FN) in breast cancer patients early and late in the chemotherapy cycle. The other two posters contain new data from the DUBLIN-3 Phase 3 non-small cell lung cancer (NSCLC) treatment program. One focuses on a quality of life (QoL) analysis that compares patients who received plinabulin with docetaxel versus those who didn’t. The other includes the results of a subgroup analysis in non-squamous NSCLC patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additional presentation details can be found below:

Title: Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo)

Abstract #: 599

Poster Session: Breast Cancer—Local/Regional/Adjuvant
Date/Time: June 6, 2022, 9 AM EDT

Presenter: Douglas W. Blayney, M.D., FASCO, Stanford University

Title: DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires

Abstract #: 9091

Session: Lung Cancer—Non-Small Cell Metastatic
Date/Time: June 6, 2022, 9 AM EDT

Presenter: Trevor Feinstein, M.D., Piedmont Cancer Institute

Title: Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 (BPI-2358-103) with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone

Abstract #: 9090

Session: Lung Cancer—Non-Small Cell Metastatic
Date/Time: June 6, 2022, 9 AM EDT

Presenter: Baohui Han, M.D., Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University

On April 28, 2022 Patrys reported that has published its Quarterly Activities Report and 4C Quarterly Cash Flow Report (Press release, Patrys, APR 28, 2022, View Source [SID1234613121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights for this Quarter have included:

Work on second engineering run of PAT-DX1 expected to complete in current quarter;
Stable cell line for production of PAT-DX3 established;
Receipt of R&D Tax Incentive Refund of $1.2 million.
Our balance sheet closed with a cash balance of $10.16M at 31 March 2022 and an additional $2M in short-term investments.

On April 28, 2022 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) reported that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022, after the close of the U.S. financial markets (Press release, CTI BioPharma, APR 28, 2022, View Source [SID1234613138]). Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 7291915. A live audio webcast of the event may also be accessed through the "Investors" section of CTI’s website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

On April 28, 2022 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 3-7, 2022 (Press release, Anixa Biosciences, APR 28, 2022, View Source [SID1234613155]). The presentation, titled "Phase 1 Trial of an alpha-Lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC)" will be presented by the study’s principal investigator, Dr. George Thomas Budd of Cleveland Clinic, Anixa’s collaboration partner.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additional presentation details can be found below:

Abstract #: TPS1125

Date/Time: June 6, 2022, 9:00 AM EDT

About Triple-Negative Breast Cancer

One in eight women in the U.S. will be diagnosed with an invasive breast cancer at some point in their lives. Approximately 10-15% of those diagnoses are TNBC, however TNBC accounts for a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence. This form of breast cancer is twice as likely to occur in African-American women, and approximately 70% to 80% of the breast tumors that occur in women with mutations in the BRCA1 genes are triple-negative breast cancer.

About Anixa Bioscience’s Breast Cancer Vaccine

Anixa’s investigational vaccine, currently in Phase 1 trials, takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in the majority of triple-negative breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing.

On April 28, 2022 Chimera Bioengineering reported that it has been selected as the winner of the Asian Fund for Cancer Research’s (AFCR) 2021 BRACE Award Venture Competition—a first-of-its-kind program for early stage oncology technology companies focused on Asian-prevalent cancers. Chimera is developing an innovative CAR-T cell therapy platform for conditional, location-specific activation to target solid tumors (Press release, Chimera Bioengineering, APR 28, 2022, View Source [SID1234613171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a result of its win, Chimera received US$500,000 in investment from AFCR and additional investments from AFCR-syndicated co-investors, bringing in a total of US$7.5 million of new funds for the company. This follows a rigorous review and evaluation process performed by the BRACE program’s three blue ribbon Committees: Selection, Judging and Investment.

BRACE Award Venture Competition winners not only receive AFCR’s investments, but also feedback and validation from key opinion leaders in the life sciences field. Additionally, the BRACE program provides participating companies with connections and access to cancer experts within AFCR’s worldwide network, as well as amplification for visibility and publicity.

"We are excited to be named the winner of the 2021 BRACE Award Venture Competition, and are thrilled by the support we have received from new investors and the connections we have made to high-caliber advisors," stated Chimera Bioengineering Chief Scientific Officer and Co-Founder Gus Zeiner, Ph.D. "We greatly value the enhanced credibility and exposure from winning the 2021 BRACE Award Venture Competition and look forward to having AFCR being a part of our journey to provide transformative therapies for cancer patients in Asia and beyond."

"During the evaluation for AFCR’s BRACE Award, I was impressed with Chimera’s insightful approach of leveraging natural mechanisms to engineer T cells," said BRACE Award Venture Competition Selection and Judging Committee Co-Chair Raju Kucherlapati, Ph.D. "The company is developing a way to engineer these critical immune system cells to selectively activate when they encounter tumor cells and deliver a payload to counteract the suppressive tumor microenvironment."

"Furthermore, Chimera’s initial data in preclinical models provide support for the ability of their platform technology to apply the curative potential of CAR-T therapies to treating solid tumors," added Dr. Kucherlapati, the Paul C. Cabot Professor of Genetics at Harvard Medical School and co-founder of multiple successful biotechnology companies, including Millennium Pharmaceuticals.

"I am proud that interest in the BRACE Award Venture Competition has spread around the world, and it is being recognized as a valuable source of investment for early stage oncology companies," expressed Asian Fund for Cancer Research Chief Executive Officer and Founder Sujuan Ba, Ph.D. "Like the potentially transformative CAR-T technology being pursued by Chimera, AFCR’s BRACE Award Venture Competition is designed to accelerate the commercialization of innovative cancer research discoveries for cancer patients, in Asia and worldwide."

"The BRACE Award Venture Competition is an annual event to support promising early stage oncology start-ups that work on cancers prevalent in Asia," exclaimed Asian Fund for Cancer Research Chairman Lance Kawaguchi. "In addition to the investment into winners such as Chimera Bioengineering, AFCR brings to the company other valuable resources, such as access to the National Foundation for Cancer Research and AIM-HI Accelerator Fund, which are founding partners of the BRACE Award Venture Competition."

Learn more about the BRACE Award Venture Competition, including the 2022 iteration of the program, now in its fourth year, at View Source

About the BRACE Award Venture Competition

The annual Bridging Research from Academia to Cancer Entrepreneurship (BRACE) program, launched in 2019, is designed to accelerate the commercialization of innovative laboratory discoveries on cancers that are prevalent in Asia. BRACE Award Venture Competitions provide start-up companies with investment capital, visibility and access to a network of world-class key opinion leaders, life sciences industry experts, investors and entrepreneurs.